Work

First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors

Year: 2015

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-015-0211-0

Authors: Patricia M. LoRusso, Priscila H. Goncalves, Lindsay Casetta, Judith A. Carter, Kevin Litwiler, Dale Roseberry, Selena Rush, Jennifer Schreiber, Heidi M. Simmons, Mieke Ptaszynski, Edward A. Sausville

Institutions: Wayne State University, Yale University, The Barbara Ann Karmanos Cancer Institute, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, College Park, Array BioPharma (United States)

Language: English

Topic: Microtubule and mitosis dynamics

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Array BioPharma

OpenAlex ID: W2039636166

FWCI: 3.246

Cites: 27

Cited by: 49

Related to: 10